# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Rachel Carson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML041-SYN
- Date: 2026-03-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Vance-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results of the breast imaging and biopsy. **S**

## History of present illness

Ms. Carson returns nine days after presenting with a firm lump in the upper outer left breast. The diagnostic mammogram and ultrasound a week ago showed a 2.4 cm irregular spiculated mass at 2 o'clock, BI-RADS 5, with normal axillary nodes. The ultrasound-guided core biopsy five days ago shows invasive ductal carcinoma, grade 2, ER 95 percent, PR 80 percent, HER2 1+ (negative), Ki-67 22 percent. Before the result was given she was asked what she wanted to know and how; she said she wanted all of it, plainly, and the report in her hand. She was told directly that the biopsy shows breast cancer, that it appears to be early and confined to the breast, and that the aim of treatment is cure. In her own words back she described an early cancer fed by estrogen, to be removed by surgery, with lymph node testing at the operation. She met Dr. Solís-Abernathy this morning and, after hearing the choice between breast-conserving surgery with radiation and mastectomy, chose breast-conserving surgery. She has no bone pain, cough, headache, or weight loss. Her ulcer pain has gone and she is taking omeprazole. She asked that her diagnosis be shared only with a close friend and her editor, and that she be the one to tell them. **S**

| Element | Detail |
|---|---|
| Interval change | Imaging BI-RADS 5; core biopsy invasive ductal carcinoma, ER and PR positive, HER2 negative |
| Disclosure | Told the diagnosis in person in plain words; report copy given; teach-back correct |
| Her decision | Breast-conserving surgery with sentinel node biopsy, after both options were explained |
| Coordination | Breast surgical oncology seen this morning |
| Privacy | Diagnosis to be shared only with the two people she names, by her |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever, or night sweats |
| Breast | Positive | Left breast lump with a small bruise from the biopsy; no nipple discharge or skin change |
| Musculoskeletal | Negative | No bone or back pain; knee stiffness unchanged |
| Gastrointestinal | Negative | No epigastric pain, black stools, or vomiting |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Worried and sleeping less since the biopsy; PHQ-9 6, GAD-7 8 |

6 systems reviewed. **S**

## Current medications

- Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healing **S**
- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/80 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 59 kg; BMI 22.2 kg/m². All vital signs are synthetic.

PHQ-9: 6; GAD-7: 8. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Composed and attentive; takes notes |
| Breasts | Left breast: 2.5 cm hard, irregular mass at 2 o'clock, mobile on the chest wall, with a small bruise at the biopsy site; no skin dimpling or nipple change. Right breast normal |
| Lymph nodes | No axillary, supraclavicular, or infraclavicular nodes |
| Abdomen | Soft; no epigastric tenderness; liver not enlarged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Invasive ductal carcinoma of the left breast, clinical stage T2 N0 (cT2 cN0 M0), hormone receptor positive, HER2 negative** (C50.412). Early breast cancer, told to her today in plain words and understood. With no symptoms of spread and a clinical stage of T2 N0, staging scans and tumor markers are not indicated. The breasts are not dense and there is a single lesion, so breast MRI is not needed. She chose breast-conserving surgery; the decision is hers and is recorded as such. **S**
   - Lumpectomy with sentinel lymph node biopsy, to be booked by Dr. Solís-Abernathy within three weeks.
   - Germline multigene panel test sent today, with genetic counseling, so the result is known before surgery.
   - Every result to be given to her in person or by telephone at a time she chooses, with a written copy.
   - Her health information shared only with the people she names.
2. **Estrogen receptor positive status** (Z17.0). ER 95 percent and PR 80 percent: endocrine therapy after surgery will be part of her treatment. **S**
   - Recurrence score on the surgical specimen, and medical oncology review after surgery.
3. **Duodenal ulcer with Helicobacter pylori, treated** (K26.9). Symptoms gone after bismuth quadruple therapy; finishing omeprazole. **S**
   - Stop omeprazole two weeks before the urea breath test.
   - Urea breath test after surgery, at least four weeks after the antibiotics.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Diagnostic mammography and ultrasound of the breast and axilla | At presentation with a palpable mass | Up to date | Done a week ago: 2.4 cm spiculated mass, BI-RADS 5; normal axillary nodes |
| Laboratory | Core biopsy with ER, PR, HER2, and Ki-67 | At diagnosis | Up to date | Invasive ductal carcinoma, grade 2; ER 95 percent, PR 80 percent, HER2 1+ (negative), Ki-67 22 percent |
| Self-management | Disclosure of the diagnosis and shared decision-making | At diagnosis and at every result | Completed today | Asked what she wanted to know; told in person in plain words; report copy given; teach-back correct; surgical choice made by her |
| Imaging | Breast MRI for extent of disease | Optional; considered for dense breasts or uncertain extent | Not indicated | Single lesion in breasts of scattered density; decided with Dr. Solís-Abernathy |
| Imaging | CT, bone scan, or PET for distant spread | Only with symptoms or clinical stage III | Not indicated | Clinical stage T2 N0 with no symptoms of spread |
| Laboratory | Tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended for early breast cancer | Not indicated | Not ordered |
| Laboratory | Germline genetic testing | At diagnosis, for breast cancer at 65 or younger | Completed today | Genetic counseling and a multigene panel today; result expected before surgery |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At diagnosis and at periodic intervals | Completed today | PHQ-9 6 and GAD-7 8, mild; offered the cancer center's counseling service, which she will consider |
| Examination | Baseline arm measurements for later lymphedema checks | Before axillary surgery | Due | To be measured at the pre-operative visit |
| Referral | Breast surgical oncology | At diagnosis | Completed today | Seen this morning; recommendations in the consultation note |
| Referral | Medical and radiation oncology | After surgery, with the surgical pathology | Due | To review the pathology and recurrence score after surgery |
| Medication safety | Avoid nonsteroidal anti-inflammatory drugs after surgery | Perioperative, after a recent duodenal ulcer | Completed today | Surgical team informed; acetaminophen for pain |
| Laboratory | Helicobacter pylori test of cure | At least four weeks after antibiotics and two weeks off a proton pump inhibitor | Due | Urea breath test planned after surgery |

## Goal progress

- Receive the biopsy result in person within ten days, explained in plain words, with a copy of the report. Outcome by 2026-03-18: Told the diagnosis in person nine days after presentation, with the pathology report in hand; teach-back confirmed her understanding. **S**
- Make each treatment decision herself after hearing the options, benefits, and harms. In progress; target 2026-04-20. **S**
- Complete surgery and radiation, then start endocrine therapy, within four months of diagnosis. In progress; target 2026-06-15. **S**
- Take adjuvant systemic therapy safely, with every safety check the drugs require done on schedule. In progress; target 2026-12-07. **S**
- Keep writing at least four mornings a week through treatment. In progress; target 2026-12-07. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Code of Medical Ethics Opinion 2.1.3: Withholding Information from Patients (2016), American Medical Association
- Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. J Clin Oncol 2017;35(31):3618-3632 (2017), American Society of Clinical Oncology
- Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Genetic result before surgery. Lumpectomy within three weeks. Primary care review about two weeks after surgery, with the pathology. **S**
- Next scheduled visit 2026-04-20: review two weeks after lumpectomy and sentinel node biopsy: full disclosure of the pathology and the adjuvant treatment decision. **S**
